A clinical-stage company developing native human monoclonal antibodies to combat drug-resistant infections, Trellis Bioscience Inc. has closed a Series C funding round, securing $6.1M. The company focuses on treating and preventing life-threatening infectious diseases.
Trellis leverages its innovative CellSpot™ technology to discover elite antibodies, with its lead candidate, TRL1068, targeting bacterial proteins critical for biofilm integrity. This novel intervention, which binds to a highly conserved epitope in most medically significant bacteria, has received Fast Track, QIDP, and Orphan Drug designations from the FDA.
